{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:07Z","timestamp":1786994407816,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.msard.2021.103022","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T11:41:01Z","timestamp":1621078861000},"page":"103022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-322X","authenticated-orcid":false,"given":"Enrique","family":"G\u00f3mez-Figueroa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-4907","authenticated-orcid":false,"given":"Alonso","family":"Alvarado-Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Garc\u00eda-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indhira","family":"Zabala-\u00c1ngeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayeli","family":"S\u00e1nchez-Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bribiesca-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Garc\u00eda-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-5664","authenticated-orcid":false,"given":"Yessica","family":"Montes-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1036-2438","authenticated-orcid":false,"given":"Erasmo","family":"Ramos-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Casallas-Vanegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Carrillo-Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"Corona-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Rivas-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Flores-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.103022_bib0001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103022_bib0002","doi-asserted-by":"crossref","DOI":"10.2174\/1871524916666160229115047","article-title":"Neuromyelitis Optica (NMO IgG+) and Genetic susceptibility, potential ethnic influences","volume":"18","author":"Alonso","year":"2018","journal-title":"Cent. Nerv. Syst. Agents Med. Chem."},{"key":"10.1016\/j.msard.2021.103022_bib0003","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1352458508100837","article-title":"Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder","volume":"15","author":"Bonnan","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103022_bib0004","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2021.103022_bib0005","doi-asserted-by":"crossref","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment Approaches for MOG-Ab-Associated Demyelination in Children","author":"Hacohen","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2021.103022_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/ncpneuro0764","article-title":"Mechanisms of disease: Aquaporin-4 antibodies in neuromyelitis optica","author":"Jarius","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.msard.2021.103022_bib0007","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.clinthera.2018.03.007","article-title":"Plasma exchange for neuromyelitis optica spectrum disorders in chinese patients and factors predictive of short-term outcome","volume":"40","author":"Jiao","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.msard.2021.103022_bib0008","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103022_bib0009","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103022_bib0010","doi-asserted-by":"crossref","first-page":"E2089","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103022_bib0011","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103022_bib0012","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/acn3.51203","article-title":"Effect of plasma exchange in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis","volume":"7","author":"Kosiyakul","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2021.103022_bib0013","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/aian.AIAN_365_19","article-title":"Plasma exchange as a first line therapy in acute attacks of neuromyelitis optica spectrum disorders","volume":"22","author":"Kumawat","year":"2019","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.msard.2021.103022_bib0014","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/1352458512471875","article-title":"Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders","volume":"19","author":"Lim","year":"2013","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103022_bib0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jca.21686","article-title":"Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica","volume":"34","author":"Lipphardt","year":"2019","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.msard.2021.103022_bib0016","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","article-title":"Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica","volume":"130","author":"Merle","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.msard.2021.103022_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: A review","author":"Pandit","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2021.103022_bib0018","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2021.103022_bib0019","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.103022_bib0020","article-title":"Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis","author":"Siritho","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103022_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101506","article-title":"A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX","volume":"38","author":"Songthammawat","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103022_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.msard.2016.02.014","article-title":"Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment","volume":"7","author":"Tackley","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103022_bib0023","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)","author":"Trebst","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2021.103022_bib0024","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103022_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577449","article-title":"Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: A systematic review and meta-analysis","author":"Yu","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2021.103022_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577449","article-title":"Efficacy of plasma exchange in acute attacks of neuromyelitis optica spectrum disorders: A systematic review and meta-analysis","author":"Yu","year":"2021","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:54:56Z","timestamp":1761900896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":26,"alternative-id":["S2211034821002893"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103022","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103022"}}